Theravance Biopharma (NASDAQ:TBPH) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Theravance Biopharma (NASDAQ:TBPH) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.13), FiscalAI reports. The business had revenue of $17.70 million during the quarter, compared to the consensus estimate of $17.78 million. Theravance Biopharma had a return on equity of 19.58% and a net margin of 104.34%.

Theravance Biopharma Price Performance

TBPH stock traded down $0.01 during trading on Friday, hitting $17.01. 237,595 shares of the stock traded hands, compared to its average volume of 351,599. Theravance Biopharma has a 1 year low of $8.33 and a 1 year high of $21.03. The firm’s 50 day moving average is $15.79 and its two-hundred day moving average is $17.37. The stock has a market cap of $876.19 million, a price-to-earnings ratio of 7.73 and a beta of 0.19.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This trade represents a 11.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

A number of institutional investors have recently made changes to their positions in the stock. Invesco Ltd. boosted its holdings in shares of Theravance Biopharma by 622.2% during the 4th quarter. Invesco Ltd. now owns 177,946 shares of the biopharmaceutical company’s stock valued at $3,329,000 after acquiring an additional 153,306 shares during the last quarter. Mackenzie Financial Corp purchased a new stake in shares of Theravance Biopharma during the 4th quarter valued at about $705,000. Susquehanna Portfolio Strategies LLC boosted its holdings in shares of Theravance Biopharma by 208.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 43,350 shares of the biopharmaceutical company’s stock valued at $811,000 after acquiring an additional 29,313 shares during the last quarter. Tang Capital Management LLC boosted its holdings in shares of Theravance Biopharma by 32.9% during the 4th quarter. Tang Capital Management LLC now owns 351,252 shares of the biopharmaceutical company’s stock valued at $6,572,000 after acquiring an additional 86,944 shares during the last quarter. Finally, Tudor Investment Corp ET AL boosted its holdings in shares of Theravance Biopharma by 272.5% in the fourth quarter. Tudor Investment Corp ET AL now owns 190,129 shares of the biopharmaceutical company’s stock worth $3,557,000 after buying an additional 139,081 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Wall Street Analysts Forecast Growth

TBPH has been the subject of several research reports. Weiss Ratings lowered shares of Theravance Biopharma from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, April 10th. HC Wainwright increased their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. TD Cowen increased their price target on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, March 23rd. Zacks Research raised shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Oppenheimer downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Theravance Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.83.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.